1. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
   Yingbo Shao et al, 2022, Frontiers in Oncology CrossRef
2. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
   Jia-Yi Huang et al, 2023, Frontiers in Oncology CrossRef
3. The novel mechanism of human norovirus induced diarrhea: Activation of PKD2 caused by HuNoVs destroyed AQP3 expression through AP2γ in intestinal epithelial cells
   Ling Huang et al, 2024, Life Sciences CrossRef
4. Transcription factor AP-2 gamma/Krüppel-like factor 10 axis is involved in miR-3656-related dysfunction of endothelial cells in hypertension
   Yaxuan Ren et al, 2023, Journal of Hypertension CrossRef
5. TFAP2C Activates CST1 Transcription to Facilitate Breast Cancer Progression and Suppress Ferroptosis
   Lin Yuan et al, 2024, Biochemical Genetics CrossRef
6. A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
   B. Liu et al, 2023, ESMO Open CrossRef
7. Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis
   Hongmei Zhang et al, 2024, Frontiers in Pharmacology CrossRef
8. Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response
   Mehrdad Hashemi et al, 2023, Biomedicine & Pharmacotherapy CrossRef